Organoid Technology in Oncology: A New Frontier for Personalized Treatment

Dear Readers,Cancer treatment is a critical area in modern medicine, presenting unique challenges for various patient demographics.One of the most significant hurdles is addressing the specific needs of older patients, who often deal with frailty and multiple comorbidities.These factors complicate therapeutic decisions and exacerbate issues related to treatment tolerance, making it a particularly complex problem to manage effectively.Furthermore, the underrepresentation of older patients in clinical trials leads to a scarcity of evidence-based data, especially for advanced therapy lines.Amidst these challenges, organoid technology emerges as a beacon of hope. 1 By accurately replicating the three-dimensional architecture and heterogeneity of tumors, organoids offer a groundbreaking platform for personalized medicine and drug development. 1This third editorial for healthbook TIMES Oncology Hematology 2024 delves into the transformative potential of organoid technology in oncology, with a spotlight on the ongoing Swiss registry study by Huptle et al., which I co-authored, focusing on optimizing treatments for older cancer patients through personalized organoid-based approaches.